M&A Deal Summary |
|
|---|---|
| Date | 2024-03-05 |
| Target | Peak Bio |
| Sector | Life Science |
| Buyer(s) | Akari Therapeutics |
| Deal Type | Merger |
| Advisor(s) | DLA Piper (Legal) |
SEARCH BY
Akari Therapeutics is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system, and the bioamine system for the treatment of rare and orphan diseases, in particular those where the complement system or leukotrienes or both complement and leukotrienes together play a primary role in disease progression. Akari Therapeutics is headquartered in London, England.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Merger M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2024 M&A | 1 of 1 |
